Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials

被引:0
|
作者
Basma Ehab Amer
Eslam Afifi
Adel Mouffokes
Abdullah Ashraf Hamad
Ahmed Mostafa Amin
Omar Ahmed Abdelwahab
机构
[1] Negida Academy,Medical Research Group of Egypt
[2] Benha University,Faculty of Medicine
[3] University of Oran,Faculty of Medicine
[4] Menoufia University,Faculty of Medicine
[5] Al-Azhar University,Faculty of Medicine
来源
Clinical Rheumatology | 2024年 / 43卷
关键词
Baricitinib; JAK inhibitors; SLE; SRI-4;
D O I
暂无
中图分类号
学科分类号
摘要
Baricitinib is a selective Janus kinase inhibitor that has recently been approved for treating certain autoimmune disorders. This meta-analysis pooled the conflicting results from all published randomized controlled trials (RCTs) about the efficacy and safety of baricitinib in patients with systemic lupus erythematosus (SLE). We systemically searched four electronic databases. RCTs comparing baricitinib versus placebo were included. Our outcomes were pooled as the risk ratio (RR) in the random effects model. Our primary outcome was the proportion of patients who achieved a SLE Responder Index-4 (SRI-4) response. A total of three RCTs, comprising 1849 patients, were included. Baricitinib 4 mg was associated with a significantly higher proportion of patients who attained SRI-4 response at week 24 (RR = 1.19, 95% CI [1.05, 1.35], P < 0.01). However, this did not reach statistical significance with baricitinib 4 mg at week 52 and baricitinib 2 mg at both week 24 and week 52 (RR = 1.13, 95% CI [0.96, 1.34], P = 0.15; RR = 1.09, 95% CI [0.96, 1.24], P = 0.20; RR = 1.05, 95% CI [0.92, 1.19], P = 0.50, respectively). The risk for serious infections was higher in the baricitinib 4 mg group (RR = 2.23, 95% CI [1.13, 4.37], P = 0.02). Baricitinib 2 mg did not show any clinical benefit. In contrast, baricitinib 4 mg might have the potential to reduce SLE disease activity; however, further research is required to evaluate its long-term efficacy. Until higher-quality evidence is developed, the benefits and risks of baricitinib should be considered before initiating its therapy. Key Points• Baricitinib is a selective Janus kinase inhibitor that has recently been approved for treating certain autoimmune disorders; however, its efficacy in patients with systemic lupus erythematosus (SLE) is still inconclusive.• In our meta-analysis, baricitinib 2 mg did not show any clinical benefit. In contrast, baricitinib 4 mg significantly reduced SLE activity in terms of SRI-4 response at week 24. However, this did not reach statistical significance at week 52.• Further studies are required to investigate the long-term efficacy of baricitinib 4 mg in patients with SLE.
引用
收藏
页码:579 / 589
页数:10
相关论文
共 50 条
  • [1] Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials
    Amer, Basma Ehab
    Afifi, Eslam
    Mouffokes, Adel
    Hamad, Abdullah Ashraf
    Amin, Ahmed Mostafa
    Abdelwahab, Omar Ahmed
    [J]. CLINICAL RHEUMATOLOGY, 2024, 43 (02) : 579 - 589
  • [2] Efficacy of baricitinib for the treatment of systemic lupus erythematosus patients: A meta-analysis of randomized controlled trials
    Panda, Aditya K.
    Ranjan, Shovit
    Sahu, Jayanta K.
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (01)
  • [3] Treatment of active systemic lupus erythematosus with baricitinib: A meta-analysis of randomized controlled trials
    Lee, Young Ho
    Song, Gwan Gyu
    [J]. LUPUS, 2023, 32 (13) : 1493 - 1500
  • [4] Baricitinib in the treatment of systemic lupus erythematosus: a systematic review of randomized controlled trials
    Shah, Hussain Haider
    Ashfaque, Faiza
    Hadi, Zeenat
    Waseem, Radeyah
    Rauf, Sameer Abdul
    Hussain, Tooba
    Anas, Zahra
    Zehra, Syeda Alishah
    Hussain, Muhammad Sheheryar
    Zuberi, Muhammad Abdul Wasay
    Haque, Md Ariful
    [J]. ANNALS OF MEDICINE AND SURGERY, 2024, 86 (08): : 4738 - 4744
  • [5] Efficacy and safety of baricitinib in treatment of systemic lupus erythematosus: a systematic review and meta-analysis
    Allam, Abdallah R.
    Alhateem, Mohamed Salah
    Mahmoud, Abdelrahman Mohamed
    [J]. BMC RHEUMATOLOGY, 2023, 7 (01)
  • [6] Efficacy and safety of baricitinib in treatment of systemic lupus erythematosus: a systematic review and meta-analysis
    Abdallah R. Allam
    Mohamed Salah Alhateem
    Abdelrahman Mohamed Mahmoud
    [J]. BMC Rheumatology, 7
  • [7] Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials
    Li, Jian
    Wei, Ming-Ming
    Song, Qin
    Guo, Xiang-Hua
    Shao, Li
    Liu, Yan
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (02) : 1500 - 1506
  • [8] Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials
    Wang, Ying
    Han, Mei
    Pedigo, Christopher E.
    Xie, Zhi-Min
    Wang, Wei-Jie
    Liu, Jian-Ping
    [J]. CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2021, 27 (10) : 778 - 787
  • [9] Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials
    WANG Ying
    HAN Mei
    Christopher E.Pedigo
    XIE Zhi-min
    WANG Wei-jie
    LIU Jian-ping
    [J]. Chinese Journal of Integrative Medicine, 2021, 27 (10) : 778 - 787
  • [10] Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials
    Ying Wang
    Mei Han
    Christopher E. Pedigo
    Zhi-min Xie
    Wei-jie Wang
    Jian-ping Liu
    [J]. Chinese Journal of Integrative Medicine, 2021, 27 : 778 - 787